Almirall strikes option deal to buy Bioniz and dermatology d...

Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and its skin cancer and alopecia drug BNZ-1.

Merck & Co's Keytruda produces mixed results in SCLC

Merck & Co’s Keytruda immunotherapy has produced mixed results in a phase 3 trial testing it in first-line extensive-stage small cell lung cancer (SCLC).

Transgene starts trials of ‘digital’ cancer vaccine with NEC

Black Diamond becomes first biotech to announce IPO in 2020

Black Diamond Therapeutics has become the first biotech to announce an IPO in 2020, asking investors to fund a clinical trial to test its new approach to tackling cancer.

Pfizer/Merck KGaA's Bavencio set for bladder cancer advantag...

Pfizer and German Merck can breathe a sigh of relief after a phase 3 trial confirmed that their immunotherapy Bavencio produces a survival benefit in bladder cancer, when used as a maintena

Merck & Co joins KRAS gold rush with Taiho and Astex collabo...

US-based Merck & Co has forged an R&D tie-up with Taiho and Astex Pharmaceuticals, focused on developing small molecule drugs targeting the KRAS gene that has become the subject of